Modeling the economic impact of medication adherence in type 2 diabetes: A theoretical approach

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 283-290

  Cobden, David S ^a   Niessen, Louis W ^b   Rutten, Frans F H ^a   Redekop, W Ken ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adherence; Cost effectiveness; Diabetes; Economics; Modeling

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH STATUS; HUMAN; MARKOV CHAIN; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; THEORETICAL STUDY; TREATMENT DURATION;

EID: 84911006612     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S12121     Document Type: Article

References (23)

1. Ramachandran A, Ramachandran S, Snehalatha C, et al. Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care. 2007;30(2):252–256.
2. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: US, 2005–2050. Diabetes Care. 2006;29(9):2114–2116.
3. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med. 2002;19(Suppl 4):1–5.
4. Cutler DM, Everett W. Thinking outside the pillbox – medication adherence as a priority for health care reform. New Engl J Med. 2010; 326(17):1553–1557.
5. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948–962.
6. Lee WC, Balu S, Cobden D, Joshi AV, Pashos C. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31–41.
7. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–75.
8. Cobden D, Niessen LW, Rutten FFH, Barr CE, Redekop WK. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health. 2010;13(1):138–147.
9. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in US managed care formulary decisions: a private payer’s experience. J Manag Care Pharm. 2006;12(9):726–735.
10. 1c targets. Int J Clin Pract. 2006;60(9):1138–1145.
11. Nathan DM. Finding new treatments for diabetes – how many, how fast … how good? New Engl J Med. 2007;356(5):437–440.
12. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–338.
13. Fone D, Hollinghurst S, Temple M, et al. Systematic review of t he use and val ue of comput er si mul at i on model l i ng i n population health and health care delivery. J Public Health Med. 2003;25(4):325–335.
14. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-Year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165–175.
15. National Center for Health Statistics, Centers for Disease Control and Prevention. NHANES 2007–2008 Dataset and Diabetes Fact Sheet Survey. http://www.cdc.gov/nchs/fastats/diabetes.htm. Accessed Sep 22, 2009.
16. 1c control among US adults with type 2 diabetes: NHANES 1999–2004. Curr Med Res Opin. 2009:25(7): 1605–1613.
17. Drug Red Book. Montvale, NJ: Medical Economics Co.; 2009.
18. Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. Am J Manag Care. 2009;15(12): 881–888.
19. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15(7): 450–456.
20. Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetes. Diabet Med. 2002; 19(8):685–688.
21. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 2006;12(6):466–471.
22. Luna B, Feinglos M. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63:1747–1756.
23. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4): 349–356.